...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews Cancer >Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial: The CLAU Randomized Trial Long-Term Outcome
【24h】

Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial: The CLAU Randomized Trial Long-Term Outcome

机译：博斯坦坦对白裔人的间歇性跛行患者心血管事件的长期效应：CLAU试验的四年后续行动：Clau随机试验长期结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionThe Clinical and Endothelial Function Assessment after Endothelin Receptor Antagonist (CLAU) trial demonstrated the effect of bosentan on the endothelial function, inflammatory status and claudication distance in Hispanic patients with incipient peripheral arterial disease (PAD). Our aim was to assess the protective effect on cardiovascular events of bosentan versus conventional anti-atherosclerosis therapy.MethodsCLAU included 56 patients with intermittent claudication, randomized 1:1 to receive bosentan for 12weeks (n=27) or placebo (n=29), associating the best medical treatment. Log-rank and hazard ratio (HR) analyses were performed to estimate the relative efficacy of bosentan in preventing incidence of major adverse events (MAE) including target limb revascularization (TLR), amputation, myocardial infarction (MI), and all-cause death; major cardiovascular adverse events (MACE) including TLR, amputation, MI, stroke, and cardiovascular-cause death; and major adverse limb events (MALE), which combines TLR and amputation.ResultsDuring the follow-up period (345months), five MAE occurred in the control group only (17.2%), including two TLR, one amputation, one stroke, and an MI. The ratio of event-free survival for MAE to 3years follow-up was higher in the group treated with bosentan (100% vs 66%, p=0.01, HR=76; 95% confidence interval 0.05-104,677, p=0.24). A similar trend was observed in incidence of MACE (100% vs 66%, p=0.01) and MALE (100% vs 80%, p=0.15).ConclusionTreatment with bosentan in the early low-to-mild stages of PAD may prevent cardiovascular events and the need for lower limb revascularization in the Hispanic population.Trial Registration ClinicalTrials.gov identifier NCT25102012.
机译：引入内皮素受体拮抗剂（CLAU）试验后的临床和内皮功能评估证明了波丝坦对初生周动脉疾病（PAD）患者的内皮功能，炎症状态和跛行距离的影响。我们的目的是评估对博塞坦的心血管事件的保护作用与常规的抗动脉粥样硬化治疗。方法包括56名间歇性跛行患者，随机1：1接受12周（n = 27）或安慰剂（n = 29），将最好的医疗相关联。进行日志秩和危险比（HR）分析以估算博斯坦坦在预防主要不良事件（MAE）发病率的相对疗效（MAE），包括目标肢体血运重建（TLR），截肢，心肌梗死（MI）和全因死亡;主要心血管不良事件（术术），包括TLR，截肢，MI，中风和心血管导致死亡;与TLR和截肢组合的主要不良肢体事件（男性）。逐步进行后续期间（345个月），在对照组中发生五个MAE（17.2％），包括两个TLR，一个截肢，一笔划和一个米。本组对博静脉（100％vs 66％，P = 0.01，HR = 76）治疗的组的无事实存活率在较高的基团中较高，HR = 76; 95％置信区间0.05-104,677，P = 0.24）。在旋转术的发病率下观察到类似的趋势（100％vs 66％，p = 0.01）和雄性（100％vs 80％，p = 0.15）。在垫的早期低至温和阶段中与波丝坦的组分可以预防心血管事件及其在西班牙裔人口中低肢体血运重建的需求。标准诊断诊所.GOV标识符NCT25102012。

著录项

  • 来源
    《Nature reviews Cancer》 |2019年第2期|共7页
  • 作者

    De Haro Joaquin; Bleda Silvia; Gonzalez-Hidalgo Carmen; Michel Ignacio; Acin Francisco;

  • 作者单位

    Getafe Univ Hosp Angiol &

    Vasc Surg Dept Ctra Toledo Km 12-300 Madrid 28905 Spain;

    Getafe Univ Hosp Angiol &

    Vasc Surg Dept Ctra Toledo Km 12-300 Madrid 28905 Spain;

    Getafe Univ Hosp Angiol &

    Vasc Surg Dept Ctra Toledo Km 12-300 Madrid 28905 Spain;

    Getafe Univ Hosp Angiol &

    Vasc Surg Dept Ctra Toledo Km 12-300 Madrid 28905 Spain;

    Getafe Univ Hosp Angiol &

    Vasc Surg Dept Ctra Toledo Km 12-300 Madrid 28905 Spain;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号